Renewable energy player BluPine Energy on Monday said it has completed the acquisition of 369 MW solar power assets from Acme Group. The 369 megawatts of solar capacity power assets are spread across Uttarakhand...
Actis unit BluPine buys Acme solar assets for enterprise value of Rs 1,700 cr
BluPine Energy, a unit of London-based private equity firm Actis, has bought solar power assets from Acme group for an enterprise value of ₹1,700 crore, said people familiar with the matter. The acquired assets are...
Lupin acquires two diabetes brands from Boehringer Ingelheim
Lupin said it has acquired diabetes brands Ondero (linagliptin) and Ondero Met (linagliptin and metformin) from Boehringer Ingelheim including the trademark rights associated with these brands for 26 million euros (Rs...
Lupin’s Brazil subsidiary acquires 9 brands from Bausch Health
Drug maker Lupin said that its wholly-owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica (MedQuímica), has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda...
Actis’ BluPine Energy buys Atha Group’s 404 MW solar power assets
Actis Llp’s BluPine Energy has acquired 404 megawatt (MW) solar power assets of Kolkata-based Atha Group, the London-headquartered private equity firm announced on Thursday. Atha’s solar assets’ enterprise value for the...
ITC acquires 10% stake in Blupin Technologies
Diversified entity ITC said it has acquired a 10.07 per cent stake in Blupin Technologies Pvt Ltd, the company behind the direct-to-consumer (D2C) brand, Mylo. The FMCG major in April had announced the acquisition of a...
Lupin completes acquisition of portfolio of brands from Anglo-French Drugs & Industries
Drug maker Lupin said it has completed the acquisition of a portfolio of brands from Anglo-French Drugs & Industries Limited (AFDIL) and its associates. The acquisition will strengthen the company’s India...
Lupin to divest entire stake in Kyowa for Rs 3,702 crore
Drug major Lupin on Monday said its board has approved selling its entire stake in Japanese subsidiary Kyowa Pharmaceutical Industry to Japan-based private equity fund Unison Capital Partners for an enterprise value of...
Lupin looks to sell Japanese arm Kyowa for $600 million
India’s Lupin Ltd is in advanced talks to sell its Japanese generics subsidiary Kyowa Pharmaceuticals for an enterprise value of $600 million to a local player as it steps up efforts to significantly cut operations in...
Lupin divests its Japanese injectables business to Abu Dhabi company
Mumbai-headquartered Lupin on Thursday announced an agreement to sell its Japanese injectables business to neo ALA Co. Ltd, a wholly-owned subsidiary of Abu Dhabi-based Neopharma group. The company said that the move...
Lupin ties up with US-based AbbVie for cancer drug, to earn $ 1 billion
Lupin on Monday announced a partnership with US-based drug maker AbbVie to develop a novel cancer drug that will potentially earn it over $1 billion in fee, milestone payments and royalties. The firm said the drug...
Lupin, Japan’s Nichi-Iko tie up to distribute biosimilar drug
Lupin Ltd, India’s third-largest drug maker, on Monday said it has tied up with Japan’s Nichi-Iko for the distribution, promotion and sale of Lupin’s recently filed biosimilar Etanercept in Japan. Etanercept is used for...